Everbeat Ring ECG Clinical Concordance Study

July 20, 2022 updated by: Grektek Inc.

Correlation of Electrocardiographic Signals Acquired by a Finger-worn ECG Sensor With a Standard 12-Lead ECG

This study is a cross-sectional observational study conducted in patients referred for routine ECG, to compare output from the everbeat finger-worn ECG device to standard of care (SOC) 12-lead electrocardiography. No intervention is involved in this study. Patients visiting the study site during the study period will be assessed for eligibility on a convenience basis, and observational data will be recorded on those eligible.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

65

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Brooklyn, New York, United States, 11217
        • BKLYNCardio
        • Contact:
          • Glenis Strachan, MD
          • Phone Number: 718-237-4067
          • Email: gasb@gmail.com
        • Principal Investigator:
          • Charles Pollack, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients aged 18-90 presenting for a routine internal medicine or cardiology clinic visit

Description

Inclusion Criteria:

  • Males or females aged 18 to 90 years.
  • Under the care of a board-certified physician and referred for a routine electrocardiogram (ECG)
  • Resting heart rate between 50 to 120 beats per minute (BPM).

Exclusion Criteria:

  • Inability to wear the everbeat ring.
  • Prior history of movement disorders including Parkinson's or benign tremors.
  • Prior history of allergic skin reactions to metal including stainless steel.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
R-wave Amplitude
Time Frame: 50 days
R Peak Amplitude intraclass correlation coefficient between test and reference devices in mm
50 days
ST-segment
Time Frame: 50 Days
Concordance in ST-segment deviation from the TP segment if present in mm
50 Days
Blinded Cardiologist Review
Time Frame: 50 Days
Identify the first six consecutive distinct readable PQRST complexes without artifacts that match between the strips for evaluation. Each reviewer will assign a pass/fail to the strips by visually assessing all 6 PQRST complexes. A "pass" is given when the morphology of the PQRST complexes appears to overlay to the unaided eye. A measurement of the R amplitude from the isoelectric baseline to the nearest millimeter for the first two QRS complexes in both the reference strip and everbeat strip. The reviewers will be blinded to the identity of the reference strip and everbeat strip.
50 Days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
User acceptance survey
Time Frame: 50 days
To assess the ease of use of the everbeat ring in a random selection of users.
50 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

August 1, 2022

Primary Completion (Anticipated)

September 20, 2022

Study Completion (Anticipated)

September 20, 2022

Study Registration Dates

First Submitted

July 4, 2022

First Submitted That Met QC Criteria

July 20, 2022

First Posted (Actual)

July 21, 2022

Study Record Updates

Last Update Posted (Actual)

July 21, 2022

Last Update Submitted That Met QC Criteria

July 20, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro00064656

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe